These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

927 related items for PubMed ID: 18421790

  • 1. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J, Park OJ, Lee YJ, Jung HM, Woo KM, Choi Y.
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [Abstract] [Full Text] [Related]

  • 2. A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN)-beta production.
    Shin HH, Lee EA, Kim SJ, Kwon BS, Choi HS.
    FEBS Lett; 2006 Mar 06; 580(6):1601-6. PubMed ID: 16480981
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.
    Bone; 2007 Oct 06; 41(4):592-602. PubMed ID: 17627913
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA.
    Bone; 2006 May 06; 38(5):678-85. PubMed ID: 16309985
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
    Park CK, Kim HJ, Kwak HB, Lee TH, Bang MH, Kim CM, Lee Y, Chung DK, Baek NI, Kim J, Lee ZH, Kim HH.
    Int Immunopharmacol; 2007 Dec 05; 7(12):1507-16. PubMed ID: 17920527
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.
    J Bone Miner Res; 2005 Apr 05; 20(4):653-62. PubMed ID: 15765185
    [Abstract] [Full Text] [Related]

  • 10. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
    Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH.
    Biochem Biophys Res Commun; 2006 Dec 08; 351(1):99-105. PubMed ID: 17052691
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.
    Biochem Biophys Res Commun; 2005 Apr 15; 329(3):839-45. PubMed ID: 15752732
    [Abstract] [Full Text] [Related]

  • 12. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):22-9. PubMed ID: 19766111
    [Abstract] [Full Text] [Related]

  • 13. Macrophage lineage phenotypes and osteoclastogenesis--complexity in the control by GM-CSF and TGF-beta.
    Lari R, Fleetwood AJ, Kitchener PD, Cook AD, Pavasovic D, Hertzog PJ, Hamilton JA.
    Bone; 2007 Feb 25; 40(2):323-36. PubMed ID: 17055352
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
    J Bone Miner Res; 2011 Mar 25; 26(3):644-56. PubMed ID: 20814972
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T.
    Immunol Lett; 2012 Feb 29; 142(1-2):34-40. PubMed ID: 22193059
    [Abstract] [Full Text] [Related]

  • 17. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K, Koike M, Ohshima S, Miyatake K, Uchiyama Y, Saeki Y, Ishii M.
    J Bone Miner Res; 2007 Oct 29; 22(10):1612-20. PubMed ID: 17576169
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
    Choi HJ, Park YR, Nepal M, Choi BY, Cho NP, Choi SH, Heo SR, Kim HS, Yang MS, Soh Y.
    Eur J Pharmacol; 2010 Jun 25; 636(1-3):28-35. PubMed ID: 20353769
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.